Several anti-PD-L1 mAbs are under investigation in various cancers including melanoma, multiple myeloma, leukemia, lymphoma, glioblastoma as well as gastric, renal cell, bladder, colorectal, hepatocellular, cutaneous, breast and NSCLC cancers. This evidence concerns the gene CD274 and glioblastoma.